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Lymphocytes characteristically express antigen recognition molecules; Ig in B 
ceils,  and T  cell receptor(s) in T  cells.  A  distinctive feature of the genetic loci 
coding for these molecules is that they must undergo a  series of hierarchically 
ordered somatic rearrangements in order to become functionally  active in mature 
lymphocytes (1-4). Ig gene rearrangements occur early during B cell differentia- 
tion (5),  and are unique to each B  cell clone, their diversity representing the 
genetic basis for antibody diversity (1,  2).  Therefore, Ig gene rearrangements 
represent specific markers of B cell lineage, clonality, and differentiation for the 
study of normal  and  neoplastic  B  cell  populations  (5-7).  The  recent  (8,  9) 
identification of the genetic locus coding for the/3 chain of the T  cell receptor 
(T0) has allowed the extension of this approach to the study of T  cells.  T ogene 
rearrangements represent markers on T cell lineage and clonality, and have been 
proven to be similarly useful in identifying individual T  cell clones (10-12). The 
availability of genetic markers of lineage and clonality for both B and T  cells, 
and of monoclonal antibodies (mAb) that detect B and T  cell-specific differen- 
tiation  antigens  allows  a  comprehensive  analysis  of lymphoid differentiation 
pathways, both in normal cell populations and in lymphoid tumors. 
In  this  respect,  a  critical  issue  is  the  lineage  specificity of Ig and  T ogene 
rearrangements in B and T  cells, respectively. Although the overall specificity of 
Ig gene rearrangements in B cells has been clearly demonstrated, several studies 
(13-2 !) have reported occasional instances in which both normal and neoplastic 
T  cells exhibit Ig gene rearrangements. Conversely, during our recent studies 
(12)  aimed at establishing the specificity of Ta gene rearrangements in T  cell 
neoplasms, we found B cell tumors in our control group that showed T ogene 
rearrangements. These preliminary observations prompted us to directly address 
the issue of the respective  B and T  cell lineage specificity of Ig and Ta gene 
rearrangements in human lymphoid tumors. 
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We  analyzed  the  patterns  of rearrangement  of Ig  and  T~  genes  and  the 
expression of mAb-defined B and T  cell-associated differentiation antigens in a 
large panel of lymphoid neoplasms representative of the various clinicopathologic 
categories  of human  lymphoid neoplasia.  We  report  that  ~10%  of lymphoid 
tumors, carrying either B or T  cell-specific phenotypic markers are bigenotypic, 
i.e., display rearrangements of both Ig and Ta genes. The implications of these 
findings for both normal and neoplastic lymphoid differentiation are discussed. 
Materials and Methods 
Specimens.  Representative samples of lymph nodes, peripheral blood and bone marrow 
were collected during the course of standard diagnostic procedures. The diagnosis of each 
lymphoid neoplasm was established by conventional clinical, cytochemical and histopath- 
ological criteria. Assignment of the B and T  cell lineage was based on results of analysis 
of cell surface markers (see below). A mononuclear cell suspension of >95% viability was 
prepared from each specimen by Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, 
N  J) density gradient centrifugation. The vast majority, >80%, of the mononuclear cells 
isolated from each specimen were cytomorphologically neoplastic. 
Cell Marker Analysis.  The presence of cell surface Ig (sIg), cytoplasmic # heavy chains 
(C#), sheep erythrocyte (E) rosette formation, HLA-DR antigens, common acute lympho- 
blastic leukemia antigen (CALLA), and terminal deoxynucleotidyl  transferase (TdT) were 
determined as previously described (22). The expression of B and T  ceil-associated and 
-restricted differentiation antigens was determined by indirect immunofluorescence em- 
ploying a panel of mAb (OKT3, OKT4, OKT6, OKT8, OKT10, OKT11, OKB2, BA-1, 
BA-2,  B1,  Leu-12,  BL1,  BL2,  BL3,  BL7)  whose  characteristics  and  distribution  of 
reactivity have  been  previously determined  (reviewed  in  22).  A  cell  population  was 
considered positive if >25% of the neoplastic cells reacted with mAb. 
DNA Extraction and Southern Blot Analysis.  DNA was prepared by cell lysis, proteinase 
K digestion, extraction with phenol, and precipitation with ethanol (23).  15 #g of DNA 
were digested with the appropriate restriction endonuclease, electrophoresed in a 0.8% 
agarose gel, denatured, neutralized, transferred to a nitrocellulose filter, and hybridized 
according to Southern (24). Filters were washed in 0.2 × standard sodium citrate, 0.5% 
sodium dodecyl sulfate, pH 7, at 60°C for 2 h (25). 
DNA Probes.  The T~ probe used in this study was derived from a human complemen- 
tary DNA (cDNA) T~ clone (YTJ-2)  isolated from the Jurkat-2 T  lymphoma cell line (a 
gift from Dr.  T. Mak, University of Ontario Cancer Institute, Toronto, Canada). This 
clone hybridizes to both the alleles (C~, and C~2) of the constant (C) region, and to one or 
more alleles of the variable (V) regions (10,  12). To generate a probe representative for 
the C region (TeC), the insert of the YTJ-2 plasmid was digested with Hinc II restriction 
endonuclease, and the 0.8 kilobase (kb) TeC-specific fragment was purified by preparative 
agarose gel electrophoresis. The Hinc II restriction site separates the V from the C regions 
by interrupting the joining (J) region (8, 10, 12). Probes for the Ig loci, representative of 
the J  region (J,) of the heavy chain (IgH) locus and of the constant k and ~ regions (Ck 
and Ca) of the light chain loci (IgL) were obtained from Dr. Stanley Korsmeyer (National 
Institutes of Health, Bethesda, MD), and have already been described (5, 6,  19). DNA 
fragments were 32P-labelled by nick translation for use as probes (26). 
Results 
We analyzed a collection of 63 lymphoid malignancies, including 33 B cell and 
30  T  cell neoplasms, representative of virtually all the major clinicopathologic 
subtypes of B and T  cell lymphomas and leukemias (Table I). DNA from these 
tumors were analyzed for Ig and Ta gene rearrangements by Southern blotting 
hybridization using various DNA clones representative of different portions of PELICCI  ET AL.  1017 
TABLE  I 
IgH and T  o Gene Rearrangement  in B and T Cell Neoplasms 
Diagnoses*  Cases studied 
Cases with rearrangements 
IgH locus  Tt~ locus 
B cell neoplasms 
ALL  11  I 1  3 
NHL  12  12  1 
CLL  3  3  1 
MM  2  2  0 
BL  5  5  0 
Total:  33  33  5 
T cell neoplasms 
ALL  4  1  4 
NHL  3  0  3 
PL  5  0  5 
ATCLL  2  I  2 
CTCL  2  0  2 
SS  2  0  2 
CLL  12  0  12 
Total:  30  2  30 
* ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin's lymphoma; 
CLL, chronic lymphocytic leukemia; MM, multiple myeloma; BL, Burk- 
itt's  lymphoma; PL, prolymphocytic leukemia; ATCLL, acute T  cell 
leukemiadymphoma; CTCL, cutaneous T  cell lymphoma; SS, Sezary 
syndrome. 
Ig and T 0 gene loci as probes.  The  IgH  locus was studied by hybridization of 
Hind III- and Eco RI-digested  DNA to a JH-specific probe,  the Ig k  locus by 
hybridization of Bam HI-digested DNA to a Ck-specific probe, and the Ig~, locus 
by hybridization of Eco RI- and Hind III-digested DNA to a Ca-specific probe. 
For  To  gene  analysis,  DNA  were  digested  with  Barn  HI  and  Eco  RI,  and 
hybridized to a  probe that recognizes rearrangements of both (C01 and C02) the 
alleles of the Ta constant gene (ToC; see Material and Methods). 
Each of the 33 B cell neoplasms displayed Ig gene rearrangements (Table I). 
Some  of these  tumors  displayed  rearrangements  of only  the  H  chain  locus, 
whereas others displayed rearrangements of both H  and L chain loci (k or k plus 
~; data not shown). Conversely, each of the 30 T  cell neoplasms displayed T0C 
gene rearrangements. However, 7 cases displayed dual rearrangements, i.e. 5 of 
33  B cell tumors (15%) displayed T o gene rearrangements, and  2  of 30 T  cell 
tumors (7%) displayed Ig gene rearrangements. 
The pattern of Ig and T o gene rearrangements of each of these seven cases is 
summarized  in  Table  II, and representative data  are illustrated in Fig.  1.  We 
have also added to these data the analysis of the T o gene variable region (ToV) 
by hybridizing Eco RI-digested tumor DNA to a T o probe that is representative 
of the C region and of one or more of the members of the presently undefined 
family of TeV genes. While a rearrangement detected by this probe demonstrates 
the involvement of this particular V  region, the lack of a  detectable rearrange- 
ment does not exclude the possibility of a rearrangement of a different V region. 1018  Ig  AND  T  CELL  RECEPTOR  GENES  IN  LYMPHOID  TUMORS 
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FIOURE  1.  Ig  and T a gene  rearrangements in  bigenotypic lymphoid  tumors.  DNA  from 
normal human fibroblasts (C) and from tumor cells (lanes 1, 2, 6, and 7 correspond to DNA 
from tumor cases in Table II) were analyzed for T a (A),  IgH (B), IgK (C) and Ig), (D) gene 
rearrangements using the restriction enzyme and DNA probe indicated at the bottom of each 
blot. 
As outlined in Table  II, two B  cell  tumors displayed  rearrangements  of both 
the C and V  regions of the T o gene, while three cases displayed rearrangements 
of only the TeC region.  These five B  cell neoplasms exhibited heterogeneity  in 
their pattern of Ig gene rearrangements. Three cases (1, 2, and 4) had rearrange- 1020  Ig  AND  T  CELL  RECEPTOR  GENES  IN  LYMPHOID  TUMORS 
ments of all three Ig loci (see cases 1 and 2 illustrated in Fig.  1); case 5 displayed 
rearrangement  of the H  chain and  K  loci, and case 3 displayed rearrangement 
only of the H  chain locus. Both T  cell tumors displayed Ig gene rearrangements 
limited to the H chain locus (see Fig.  1); case 6 exhibited rearrangement of both 
C and V regions of the T o gene, and case 7 exhibited rearrangement of the ToC 
region but no rearrangement  of the particular V region explored by our probe. 
Finally, we investigated whether the seven bigenotypic neoplasms had a  cor- 
responding biphenotype, i.e. expressed both B and T cell differentiation markers. 
We therefore extended our preliminary  diagnostic immunophenotypic analysis 
of these seven cases to include analysis with our large panel of B or T  specific 
mAb. As shown in Table II, not one of the five B cell neoplasms expressed any 
T  cell-restricted antigens, and neither one of the two T  cell neoplasms expressed 
any B cell-associated antigens.  It is important  to note that these neoplasms are 
representative of both the early and late stages of B and T  cell differentiation. 
We conclude that bigenotypic lymphoid neoplasms displaying a  mixed T  and B 
genotype appear to retain  B and T  cell lineage-restricted cell surface antigens, 
and do not display a mixed immunophenotype. 
Discussion 
In  the  studies presented  here,  we report  seven human  lymphoid  neoplasms 
that show rearrangements  of both Ig and T 0 genes. This group of bigenotypic 
lymphoid  tumors  is not irrelevant,  since it  represents  -11%  of the  malignant 
lymphoproliferative disorders that we investigated.  The test group consisted of 
a heterogeneous group of 63 lymphoid neoplasms expressing diverse phenotypes 
consistent with various stages of differentiation in the B and T  cell lineages, and 
representative  of the  majority  of the  significant  clinical  and  histopathological 
subtypes of lymphoid neoplasia. 
The  bigenotype  appears  to  be  less  frequent  in  T  cell  neoplasms,  where  it 
occurred in only 2  of 30 of the cases (7%) studied.  The frequency of Ig gene 
rearrangements  in freshly isolated T  cell neoplasms in this series, 7%, is signifi- 
cantly lower than  the 50%  frequency rate previously reported (13,  15,  18,  19) 
to occur in T  cell lymphoid cell lines in which, although not demonstrated,  the 
presence  of T~  gene  rearrangements  can  be  reasonably  assumed.  Our  data 
establish  the  low frequency of Ig gene rearrangement  in primary  cell tumors, 
and suggest that similar rearrangements may frequently occur and/or be selected 
for during continuous cell culture. 
The occurrence of the mixed genotype appears to he approximately twice as 
frequent in B cell than  in T  cell neoplasms, since it occurred in five out of 33 
(15%)  of the  cases  in  this  series.  The  difference  between  the  frequency  of 
combined  rearrangements  in  B  and  T  cell  tumors  appears  to  correlate  with 
qualitative differences in  the pattern  of gene rearrangements.  In fact, Ig gene 
rearrangements  that  occur in T  cell tumors have been limited to the  H  chain 
locus in all cases. These rearrangements  most likely reflect a partial  D-J joining 
event,  as  demonstrated  in  a  number  of human  and  murine  T  cell  lines  (14). 
Conversely, our data indicate that the T~ gene rearrangements  that occur in B 
cell tumors may involve both C and V regions, indicating that a full V-D-J joining PELICCI  ET  AL.  1021 
event may have occurred. Insights into the significance of this difference will be 
provided by studies of specific mRNA and protein expression in these cells. 
Our findings in tumor cells raise the question of whether combined Ig and Ta 
rearrangements  represent a  consequence of neoplastic transformation,  or can 
occur during normal lymphoid differentiation. In the former case, it is possible 
that the dual genotype is a transformation-related event that reflects the derange- 
ment of the genetic machinery regulating differentiation in the neoplastic cells. 
Thus, these bigenotypic lymphoid neoplasms would represent examples of line- 
age infidelity within the lymphoid lineage comparable to what has been observed 
between the lymphoid and the myeloid lineages (27). However, these bigenotypic 
lymphoid neoplasms retain  a  completely fidelous immunophenotypic pattern, 
while the observed cases of lymphoid-myeloid lineage infidelity are biphenotypic. 
An  additional,  attractive  possibility  is  that  these  unorthodox  rearrangements 
may involve oncogene sequences contributing to the pathogenesis of these tumors 
(28-31). 
Alternatively,  the dual genotype may also occur in normal cells, as strongly 
suggested by several  studies (16,  17)  reporting the occurrence  of Ig H  chain 
locus rearrangements and expression in mouse thymocytes and lymphocytes. If 
this is the case, then several interpretations can be proposed to attempt to explain 
the significance of this phenomenon. (a) This event may have some functional 
significance, and  may identify a  subpopulation of bipotent lymphoid cells, i.e. 
with both B and T  cell properties. We consider this theoretical possibility rather 
unlikely  in  view  of our  observation  that  each  of our  bigenotypic neoplasms 
retained  a  pure  B  or  T  cell  phenotype.  (b)  Dual  genotypes  may  reflect  the 
existence of a  differentiative step during lymphoid differentiation in which a 
committed B or T  cell retains the potential to switch to the other lineage. The 
fidelity of the immunophenotype may represent the final lineage commitment 
of the cell, whereas the dual genotypic markers remain as an irreversible footprint 
of the previous commitment. (c) The dual genotype may reflect the concomitant, 
perhaps casual, activation in T  and B cells of common molecular mechanisms, 
regulating the rearrangements of these loci. This notion is consistent with the 
reported (4) partial homology between sequences involved in the joining events 
in Ta and Ig H  chain genes. 
Finally, our findings bear important implications for the immunodiagnosis and 
classification of human lymphoproliferative malignancies. It has been proposed 
that Southern blot analysis and demonstration of Ig and Ta gene rearrangements 
represents  the  definitive method by  which  to determine  the  lineage and  the 
clonality  of  lymphoid  populations  that  display  equivocal  immunophenotypic 
patterns.  However, our data presented here strongly suggests that the lineage 
specificity of these  rearrangements  is  not  absolute.  We  conclude  that  only a 
multiparametric approach (22),  employing immunophenotypic, genotypic, and 
in some instances functional testing, allows a conclusive lineage definition of all 
lymphoid neoplasms. 
Summary 
Ig and T o gene rearrangements can be used as genetic markers of lineage and 
clonality in the study of B and T  cell populations. We have addressed the issue 1022  Ig  AND  T  CELL  RECEPTOR  GENES IN  LYMPHOID TUMORS 
of the respective B and T  lineage specificity of these rearrangements by analyzing 
a  panel of 63  lymphoid tumors  representative of the various clinicopatho]ogic 
categories of both B and T  neoplasias. We report that ~ 10% of the cases tested 
displayed rearrangements of both Ig and T¢ genes. Despite their dual genotypic 
pattern, these tumors retain a pure immunophenotype, i.e. they display either B 
or  T  cell  lineage-restricted  cell  surface  antigens.  The  implications  of  these 
findings for both normal and neoplastic lymphoid differentiation are discussed. 
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